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Abstract  1 
 2 
Polymorphonuclear neutrophils (PMNs) are the most abundant circulating blood 3 
leukocytes. They are part of the innate immune system and provide a first line of defense by 4 
migrating toward areas of inflammation in response to chemical signals released from the site.   5 
Some solid tumors, such as breast cancer, also cause recruitment and activation of PMNs and 6 
release of myeloperoxidase. In this study, we demonstrate that administration of luminol to mice 7 
that have been transplanted with 4T1 mammary tumor cells permits the detection of 8 
myeloperoxidase activity, and consequently, the location of the tumor. Luminol allowed 9 
detection of activated PMNs only two days after cancer cell transplantation, even though tumors 10 
were not yet palpable. In conclusion, luminol-bioluminescence imaging (BLI) can provide a 11 
pathway towards detection of solid tumors at an early stage in preclinical tumor models. 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
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1. Introduction 10 
 11 
Cancer is a major cause of disease and death in the United States and other countries 12 
around the world. For example, the American Cancer Society estimates that 580,350 people will 13 
die of cancer in the U.S. in 2013 [1]. Detecting tumors at earlier stages could significantly 14 
improve therapeutic outcomes [2, 3]. In pursuing this goal, understanding the tumor 15 
microenvironment may facilitate tumor diagnosis at the earliest stages. It has been known that 16 
tumor microenvironment differs from that of normal tissue in that it is often characterized by low 17 
pH, hypoxia, over-expressed proteases [4], and infiltration of defensive and immune cells [5]. 18 
 19 
These features can potentially be exploited for detection and treatment. Several imaging 20 
techniques have been used to examine the tumor microenvironment, such as optical imaging, 21 
positron emission tomography (PET) and magnetic resonance imaging (MRI) [4, 6-12] 22 
Bioluminescence imaging (BLI) is a non-invasive imaging technique used in pre–clinical 23 
oncology research to image tumors by generating visible light, that is usually generated by 24 
luciferase-expressing cells [2, 13]. The luciferase-based BLI mechanism involves the oxidation 25 
of luciferin in the presence of adenosine tri-phosphate (ATP), magnesium (Mg2+) and molecular 26 
oxygen (O2) to create an electronically excited oxy-luciferin, which emits visible radiation in the 27 
yellow-green to yellow-orange spectrum, with an emission maximum of 560nm [2, 13]. Firefly 28 
luciferase transfected mouse mammary gland tumor cells 4T1-luc2 show stable light emission in 29 
the presence of luciferin and permit the detection of early tumors [2]. In contrast to luciferase-30 
based BLI mechanism, Liu et al., showed beta galactosidase based chemiluminescent imaging 31 
 4 
 
for in vivo detection of tumors expressing a beta galactosidase transgene[14] .  However, 1 
naturally occurring cancers do not express luciferase. Therefore, luciferase-based BLI is not 2 
available when treating cancers in humans and/or not transfected tumors in mammals. Note that 3 
in the research reported here, luciferase-based BLI is only used to define the region of interest. 4 
 5 
Luminol (5-amino-2,3-dihydrophthalazine-1,4-dione) is a known chemiluminescent 6 
molecule that emits light at maximum of 425 nm when oxidized [15, 16]. Luminol has been used 7 
in various fields, such as biochemistry, analytical chemistry, and clinical diagnostics for 8 
detecting reactive intermediates [17]. For instance, luminol has been used as an analytical tool 9 
to examine the role of granulocyte-derived reactive oxygen species in heart muscle damage, to 10 
screen polymorphonuclear leukocyte function in patients with diabetes mellitus, and to detect 11 
leukocyte activity in patients with peritonitis [15, 18]. Luminol detects phagocytic oxidative bursts 12 
and subsequent myeloperoxidase (MPO) activity [17]. Gross et al. have demonstrated that 13 
luminol-based imaging can be used for quantitative longitudinal monitoring of MPO activity in 14 
animal models of acute dermatitis, mixed allergic contact hypersensitivity, focal arthritis and 15 
spontaneous large granular lymphocytic tumors[17]. The work presented here consists of 16 
tailoring their detection method for revealing early breast tumors (4T1) in mice. Chronically 17 
inflamed tissues like cancer are populated by defensive cells, such as neutrophils, monocytes, 18 
and macrophages, which can produce reactive oxygen species (ROS) by respiratory bursts and 19 
subsequent chemical reactions. Many of these ROS react with luminol and produce light by 20 
means of luminol chemiluminescence [19].Since this chemiluminescence occurs from a 21 
chemical and oxidizers that are produced by enzymes in living cells, we will use the term 22 
luminol-based bioluminescence imaging (BLI). Here, we present first evidence that 23 
administration of luminol to mice that have been transplanted with 4T1 mammary tumor cells 24 
permits early stage imaging of tumors by bioluminescence-based detection of MPO activity.  25 
 26 
 27 
2. Theory of Luminol-Based Bioluminescence  28 
	29 
When PMNs are activated in inflamed tissues such as tumors, they start releasing 30 
myeloperoxidase (MPO) [20, 21]. MPO is an abundant protein produced in azurophilic granules 31 
of neutrophils, where it can constitute more than 5% of the granule’s protein [22]. Respiratory 32 
burst is initiated by phagocytic NADPH oxidase (Phox).  Phox reduces molecular oxygen (O2) to 33 
 5 
 
give superoxide anions (O2.-). In the presence of protons (H+), the superoxide anion reacts to the 1 
hydroperoxy free radical (HO2.). Superoxide and hydroperoxy free radicals disproportionate to 2 
hydrogen peroxide (H2O2) and molecular oxygen [23]. Superoxide dismutase (SD) accelerates 3 
this reaction. During PMN activation, MPO catalyzes the reaction of H2O2 and chloride ions (Cl-) 4 
to produce hypochlorous acid (HOCI) [17]. In turn, HOCI can oxidize luminol, which triggers 5 
chemiluminescence [17]. MPO can also directly utilize superoxide anion as a substrate for 6 
peroxidase-catalyzed oxidation of luminol [17]. The manifold of reactions is shown in scheme 1.  7 
 8 
Luminol can detect activated neutrophils, which often accumulate in tumor tissue.  9 
Therefore, luminol may be a clinically relevant method for detecting tumors in vivo.  To verify the 10 
ability of luminol to detect tumors, 4T1 tumors bearing a firefly luciferase gene were generated 11 
in Balb/c mice.  Luciferin/luciferase is a well-known imaging system that can detect luciferase 12 
bearing cells very specifically in vivo.  Luciferase detection is clinically irrelevant, though, 13 
because clinical tumors do not contain luciferase genes.  If luminol imaging could produce 14 
images comparable to luciferin in luciferase bearing tumors it would be validated as a tumor 15 
detection system.  Therefore, luminol bioluminescence was compared to the highly-sensitive but 16 
clinically-irrelevant luciferin bioluminescence.  We were able to demonstrate using 4T1 tumors 17 
in BALB/c mice that MPO detection from neutrophils is especially suited to image tumors very 18 
early after implantation.  19 
 20 
 21 
3. Material and Methods 22 
 23 
3.1 Materials and Cell Culture 24 
Mouse mammary gland adenocarcinoma tumor cell line 4T1luc2 was purchased from 25 
Caliper Life Sciences, Hopkinton, MA. This cell line has been engineered to stably express the 26 
firefly luciferase gene luc2 [24]. Cells were grown in RPMI1640 medium supplemented with 10% 27 
fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO) and 1% penicillin/ streptomycin 28 
(Invitrogen, Grand Island, NY). Cells were incubated at 37°C at 95% humidity in 5% CO2. 29 
Luminol sodium salt was purchased from Gold Biotechnology Inc., St. Louis, MO. Luciferin was 30 
purchased from Caliper Life Sciences.  31 
 32 
 33 
 6 
 
3.2 Mouse tumor model 1 
9 week old female BALB/c mice were obtained from Charles River Laboratories, 2 
Wilmington, MA. Mice were maintained according to approved IACUC procedures (3060) in the 3 
Comparative Medicine Group facility of Kansas State University. Before 4T1 luc2 cells 4 
transplantation, mice fur was clipped on the ventral surface to identify mammary fat pads. 1X105 5 
4T1luc2 cells in 25 µl phosphate buffered saline (PBS) were transplanted orthotopically into the 6 
fat pad of mammary gland number seven. 4T1luc2 cell line expresses the firefly luciferase gene 7 
and tumors can be identified by D-luciferin imaging.  Control mice were injected with 25 µl 8 
phosphate buffered saline (PBS) orthotopically into mammary fat pad number seven.  9 
 10 
 11 
3.3 Bioluminescence imaging 12 
As a positive control, the light sensitive substrate D-luciferin (15mg/mL in 1X PBS) was 13 
given to the mice intraperitoneally at a dose of 150mg/kg.To demonstrate luminol-dependent 14 
bioluminescence, a three hour gap was allowed between D-luciferin and luminol injections. After 15 
that, mice were injected intraperitoneally with luminol (30mg/mL in water) at a dose of 300mg/kg. 16 
In both cases, mice were placed beneath the CCD camera in an IVIS Lumina II imaging system 17 
(Caliper Life Sciences) and retained under isoflurane anesthesia (1.5%-2.0%) for the period of 18 
imaging. Bioluminescence was recorded 5 minutes after D-luciferin and luminol injections. For 19 
D-luciferin, mice were imaged on days 1, 2 and 3 after 4T1luc2 cells or PBS sham injection. For 20 
luminol, mice were imaged on days 1, 2, 3, 4, and 5 after 4T1luc2 cells or PBS sham injection. 21 
The area of 4T1luc2 cell or PBS injection (mammary pad 7) was selected as the region of 22 
interest (ROI) on bioluminescent images (Figure1). Boundaries of the ROI were defined based 23 
on the luminescence signal in 4T1luc2 cell-injected mice, and the same size area was used in 24 
PBS-injected mice. The average radiance (p/s/cm2/sr) from that ROI was used as measurement 25 
for analysis. The duration of detectable bioluminescence occurring from firefly luciferase was 26 
found to be 30 minutes after luciferin administration. In order to avoid any potential overlap, we 27 
waited three hours after luciferin injection to administer luminol. 28 
 29 
Figure1 30 
 31 
 32 
 33 
 34 
 7 
 
3.4 Luminol injection kinetics 1 
To determine whether the luminol injection route affects luminescence peak signal time 2 
at the tumor site, two mice were injected intravenously with luminol (30mg/mL in water) at a 3 
dose of 300mg/kg. Two other mice were injected intraperitoneally with luminol (30mg/mL in 4 
water) at a dose of 300mg/kg.  Both groups were placed beneath the CCD camera of the IVIS 5 
system and retained under isoflurane anesthesia (1.5%-2.0%) for the period of imaging (55 6 
minutes). Area of 4T1 cells or PBS injection (mammary pad 7) on bioluminescent images was 7 
selected as the region of interest (ROI). Boundaries of the ROI were defined based on the 8 
luminescence signal on 4T1 cells-injected mice, and the same size area was used in PBS-9 
injected mice. The average radiance (p/s/cm2/sr) from that ROI was used as measurement for 10 
analysis.  11 
 12 
4. Results  13 
 14 
4.1 D-luciferin imaging 15 
 4T1luc2 cell-transplanted mice showed a bioluminescence signal at mammary fat pad 16 
number seven as early as day 1 with D-luciferin imaging (Figure2A), suggesting that with D-17 
luciferin imaging we can detect 4T1luc2 cells before they form palpable tumors. This finding is in 18 
agreement with the literature [2]. Note that luciferin bioimaging is used as positive control for 19 
luminol imaging. Mice injected with PBS showed no bioluminescence signal with D-luciferin 20 
imaging (Figure2A). D-luciferin imaging of mice on days 2 and 3 showed a bioluminescence 21 
signal at the 4T1luc2 cell injection site (Figure 2A); the intensity of bioluminescence (average 22 
radiance) has an increasing trend over time (Figure2B), indicating that at least during the early 23 
days following bioluminescent tumor cell transplantation, an increase in tumor size can be 24 
observed by D-luciferin imaging.  25 
 26 
Figure 2A,B  27 
 28 
4.2 Luminol imaging 29 
Bioluminescence imaging after luminol injection in mice showed a bioluminescence 30 
signal at the 4T1luc2 cell injection site (mammary fat pad number seven) on all imaged days 31 
starting from Day 1 (Figure 3A, red lines). Control mice injected with PBS showed weak signal 32 
at the injection site after luminol was administered on Day 1 but no signal on Day 2 (Figure 3A, 33 
 8 
 
blue lines). Apart from the tumor cell injection site, mice showed luminescence at other areas, 1 
primarily in the abdominal region. This may be because of peritonitis caused by luminol 2 
intraperitoneal injection. Also, some mice showed rectal light (Figure 3A) because luminol is 3 
known to be removed from the blood and excreted in the faces and this signal is likely due to 4 
this natural excretion. There were also small areas of signal in the neck-head region to skin 5 
nicking induced by clipping.  Bioluminescence signal intensity from the injected area (mammary 6 
fat pad number seven) started increasing 2 days after 4T1luc2 cell transplantation, and over 7 
time, the signal intensity increased (Figure 3B). Also, D-luciferin and luminol bioluminescence 8 
intensities showed positive correlations on day 1(R2 = 0.84), day 2(R2 = 0.83) and day 3(R2 = 9 
0.82) (Figure 3C). 10 
 11 
Figure 3A,B,C 12 
 13 
 14 
4.3 Luminol injection kinetics 15 
To see whether there is any difference in bioluminescence peak signal time at the 16 
4T1luc2 cell injection site; mice were imaged after intravenous or intraperitoneal luminol 17 
injection. In both cases mice showed peak bioluminescence signal at the tumor area between 18 
five and 15 minutes after luminol injection (Figure 4A,B); the signal lasted for one hour after the 19 
luminol injection. Consequently, intravenous injection of luminol resulted in the stronger 20 
bioluminescence signals. These results are in principal agreement with earlier imaging 21 
experiments in mice utilizing firefly luciferase[9, 25]. Since both luminol and luciferin are small 22 
molecules, it is not surprising that similar in-vivo kinetics are observed. 23 
 24 
Figure 4A, B 25 
 26 
5. Discussion 27 
The work described above demonstrates that orthotopically transplanted 4T1luc2 28 
mammary adenocarcinoma cells can be successfully imaged by means of luminol-based 29 
biolumincescence imaging even before tumors are palpable. Although control mice injected with 30 
saline did show a small signal, the control bioluminescence signal disappeared after two days, 31 
in contrast to the transplanted tumor signal. Also, mice showed luminescence at other areas 32 
apart from the tumor cell injection site, primarily in the abdominal region. This may be because 33 
 9 
 
of peritonitis caused by intraperitoneal luminol injection.  Skin nicks due to clipping also 1 
produced small signals in the neck and head region on days 1 and 2 after tumor cell inoculation.  2 
The intensity of the luminol-based BLI in mammary fat pad 7 increased over time after tumor 3 
transplantation.   This is the first report of early tumor imaging of solid carcinomas using luminol 4 
alone in a preclinical model without additional components.  Previously, luminol-based BLI was 5 
shown to be effective in early imaging in a transgenic preclinical model of a hematological 6 
cancer [17].  Zhang et al. studied the MPO dependence of the luminol bioluminescence signal 7 
[21]. When luminol was injected into MPO-positive mice and MPO-deficient mice, no 8 
luminescence signal was observed in the group of MPO-deficient mice. Based on these studies 9 
[17, 20], it is our paradigm that the luminol BLI signal we detected here is based on MPO activity 10 
that been released from activated neutrophils because of tumor transplantation [17].   11 
The emission maximum of luminol-based bioluminescence is at = 425 nm[26]. At this 12 
wavelength, tissue penetration (decrease of the luminescence signal to 1/e) is estimated at 0.5 13 
mm [27], corresponding to a tissue path length (99% light absorption) of approximately 2.2 mm. 14 
In conclusion, the penetration depth of luminol-based bioluminescence is not well suited for 15 
imaging deep-seated tumors [21]. Therefore, two strategies can, principally, be pursued for 16 
achieving enhanced bioluminescence signals. The first strategy comprises measures to 17 
enhance the photon flux of the light emitted at 425nm. It has been reported that -cyclodextrin 18 
can enhance luminol luminescence [28]. Another study employed the chemiluminescent probe, 19 
L-012 (8-Amino-5-chloro-7-phenylpyrido[3,4-d]pyridazine-1,4(2H,3H)dione), a substrate that has 20 
the potential of generating more light than luminol, for detecting MPO activity [29, 30]. The 21 
second strategy, described by Zhang et al. is using NIR-emitting Q-dot nanoparticles, which 22 
absorb the luminol-based bioluminescence at 425 nm and reemit them as NIR photons [21]. It is 23 
noteworthy that the light penetration depth in the near infrared region is approximately 10 times 24 
larger than in the blue region of the visible spectrum [27]. The drawback of this strategy is that 25 
most nanoparticles of this type are cytotoxic [31].Therefore, administering additional imaging 26 
agents, such as NIR-emitting nanoparticles may not be an option when imaging tumors in 27 
humans to observe their response to treatment. But, exploring additional measures of 28 
enhancing the luminescent signal may be useful for increasing the ability of luminol to detect 29 
deeper tumors.  30 
It has been reported that the numbers of neutrophil granulocytes increase in the 31 
circulation in animals and humans with a variety of tumors [32].Tumor cells secrete different 32 
cytokines and chemotactic factors which can cause recruitment and activation of neutrophils 33 
 10 
 
and other immune cells. Some examples are interleukins (IL-6 and IL-8) [33, 34], as well as 1 
interferons (IFN-γ, INF-α, INF-β), and tumor necrosis factor-α (TNF-α)[35]. Furthermore, 2 
neutrophils are known to be a major component of inflammatory infiltrates in glioma [36], 3 
micropapillary carcinoma in the pancreas [37], human fibrosarcoma [38] , prostate carcinoma 4 
[39] and gastric carcinoma [40]. Also, it has been reported that neutrophils accumulate in the 5 
lungs before the arrival of metastatic cells in breast cancer models [41]. These studies, which 6 
demonstrate neutrophil infiltration in different types of tumors, suggest that luminol-based BLI 7 
detection of infiltrating neutrophils has potential for early human tumor detection.  8 
Luminol has been used in humans for treatment of alopecia areata [42]; those studies 9 
showed it to be safe and rapidly excreted, with no toxic side effects observed. In conclusion, 10 
luminol or other luminescent substrates could potentially be used in human patients for imaging 11 
tumors. Although this study is a proof-of-principle, the method reported here could potentially be 12 
developed to screen for recurrence of other superficial cancers. 13 
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7. Figure captions 1 
 2 
Scheme 1: Neutrophil-mediated oxidation and chemiluminescence of luminol (Phox: NADPH 3 
oxidase, SD: Superoxide Dismutase, MPO: myeloperoxidase) 4 
Figure 1. Bioluminescence measurement. Mammary pad 7, the site of 4T1luc2 cell injection 5 
(red lines, left four mice) or PBS injection (blue lines, right two mice), was selected as the region 6 
of interest (ROI). The average radiance (p/s/cm2/sr) from that ROI was used as measurement 7 
for analysis.  8 
Figure 2. D-luciferin imaging. A D-luciferin injections were given to the mice intraperitoneally 9 
on days 1, 2, and 3 after 4T1 luc2 cell injection. Red lines (left four mice): mice injected with 4T1 10 
luc2 cells in mammary fat pad number seven. Blue lines (right two mice): control mice injected 11 
with PBS in mammary fat pad number seven. A luminescence signal was observable at 12 
mammary fat pad number seven as early as on day 1 when imaging with D-luciferin in 4T1 luc2 13 
cells injected mice. B Graph of the intensity of luminescence (average radiance, p/s/cm2/sr) is 14 
showing an increasing trend from day 1 to day 3, suggesting that an increase in tumor size can 15 
be observed by D-luciferin imaging, as shown by  previous studies[2]. 16 
Figure 3. Luminol imaging. A Luminol injections were given intraperitoneally to 4T1-bearing 17 
and control groups of mice on days 1 to 5 after 4T1luc2 cell injection or PBS injection. Red lines 18 
(left four mice): mice injected with 4T1luc2 cells. Blue lines (right two mice): control mice 19 
injected with PBS. Luminol signal was seen at the 4T1luc2 cell injection site (mammary fat pad 20 
number seven) on all the imaged days starting from day 1. PBS injected mice (right two mice) 21 
showed virtually no signal at mammary fat pad number seven, but showed signal mainly in the 22 
abdominal region. B Bioluminescence signal intensity (average radiance (p/s/cm2/sr) at 23 
mammary fat pad number seven increased by 3 days after 4T1luc2 cell transplantation, and 24 
over time, the signal intensity increased. C Comparison of D-luciferin and luminol 25 
bioluminescence intensities showed positive correlation for day 1(R2-0.84), day 2(R2-.83) and 26 
day 3(R2-0.82).  27 
Figure 4. Luminol injection kinetics. A Comparison of intravenous (two mice, right) and 28 
intraperitoneal (two mice, left) luminol injections to observe the difference in bioluminescence 29 
peak signal time at the 4T1luc2 cell injection site. Mice were imaged every 10 minutes with an 30 
accumulation time of 5 minutes, resulting in a total imaging time of 55 min. after luminol 31 
injections.. Luminescence peaked between 5 and 15 minutes regardless of injection method. B 32 
 12 
 
Graph showing the bioluminescence signal (average radiance, p/s/cm2/sr) intensity after 1 
intraperitoneal and intravenous administration.   2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
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